Buyer beware: an IP checklist for life sciences investors

This is an Insight article, written by a selected partner as part of IAM's co-published content. Read more on Insight

Whether caused by the paucity of new products in pharma pipelines or the lure of a highly marketable new technology, investors often become comfortable with a deal before effectively evaluating the target’s intellectual property portfolio. IP issues that are overlooked often decrease the value of the investment and open the door for future debilitating litigation.


Unlock unlimited access to all IAM content